Backed by Believers
DAOdiscovery is supported by strategic investors and Switzerland's national innovation agency, united by a shared conviction in the power of diazo ylide chemistry to transform drug discovery.
Our Backers
Investors & Grants
Omescon GmbH is a strategic industry investor bringing deep expertise in pharmaceutical process systems, manufacturing, and technology commercialisation to DAOdiscovery. Their investment reflects a conviction in both the science and the team behind the platform.
↗ Visit Omescon GmbH
The Swiss Innovation Agency awarded DAOdiscovery an Innosuisse Startup Grant in 2026, Switzerland's most competitive early-stage innovation programme. Beyond funding, Innosuisse provides structured coaching and industry connections to accelerate the path from academic discovery to pharmaceutical application.
↗ Visit InnosuisseA third engagement is currently under discussion and will be announced soon. We are in active conversations with strategic and financial backers aligned with our vision for next-generation drug discovery.
The Investment Case
Why DAOdiscovery
Patented diazo ylide chemistry, AI-powered pre-selection, and peer-reviewed validation, the convictions behind a platform built to unlock unexplored 3-D chemical space.
Our diazo ylide synthesis and key intermediates are IP-protected, gating access to strained 3-D scaffolds no competitor can make.
The engine collapses hundreds of millions of accessible molecules into a focused, disease-relevant set. Chemistry first, then AI.
Validated in Nature Chemistry and Science: the platform rests on published, independently reproduced science.
Asset-light, university-anchored operations plus non-dilutive Innosuisse backing stretch every franc toward first revenue.
Use of Funds
What the Pre-Seed round enables
We are raising $1.5M in Pre-Seed funding to automate and scale our AI-guided spiropentane synthesis and to launch first pilot libraries with pharma partners. Asset-light by design, with an annual burn of roughly €130 to 150k.
Build out automated, AI-guided spiropentane synthesis so we can make and validate candidates faster.
Expand the patented scaffold library and the virtual enumeration pipeline behind it.
Execute first pilot libraries with pharma partners against real disease targets.
File and strengthen patents across new scaffolds and synthetic routes.
Walk the way with us
Any interest to invest in the future?
We are actively building relationships with pharma companies, biotech investors, and strategic partners who share our vision for next-generation small molecule drug discovery. Let's talk.
↗ Get in TouchInvestor deck and data room available upon request.